These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21449680)

  • 21. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E; Vécsei L
    Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
    Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can blood gene expression predict which patients with multiple sclerosis will respond to interferon?
    Kaminski N; Achiron A
    PLoS Med; 2005 Feb; 2(2):e33; quiz e51. PubMed ID: 15736992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.
    Vandenbroeck K; Comabella M
    J Interferon Cytokine Res; 2010 Oct; 30(10):727-32. PubMed ID: 20836710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    Neuhaus O; Stüve O; Archelos JJ; Hartung HP
    J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment and treatment trials in multiple sclerosis.
    Kieseier BC; Wiendl H; Hemmer B; Hartung HP
    Curr Opin Neurol; 2007 Jun; 20(3):286-93. PubMed ID: 17495622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
    Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
    Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis.
    Carmona O; Masuet C; Alía P; Moral E; Alonso-Magdalena L; Casado V; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2011; 65(3):132-7. PubMed ID: 21325856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
    Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
    Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.
    Grossman I; Avidan N; Singer C; Goldstaub D; Hayardeny L; Eyal E; Ben-Asher E; Paperna T; Pe'er I; Lancet D; Beckmann JS; Miller A
    Pharmacogenet Genomics; 2007 Aug; 17(8):657-66. PubMed ID: 17622942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach.
    Vosslamber S; van Baarsen LG; Verweij CL
    Pharmacogenomics; 2009 Jan; 10(1):97-108. PubMed ID: 19102719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.
    Rudick RA; Rani MR; Xu Y; Lee JC; Na J; Shrock J; Josyula A; Fisher E; Ransohoff RM
    PLoS One; 2011; 6(5):e19262. PubMed ID: 21602934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.
    Cunningham S; Graham C; Hutchinson M; Droogan A; O'Rourke K; Patterson C; McDonnell G; Hawkins S; Vandenbroeck K
    Clin Pharmacol Ther; 2005 Dec; 78(6):635-46. PubMed ID: 16338279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.